Skip to content
by Legal Desire
16 November 2026

DLA Piper advises Heron Therapeutics on sale of substantially all assets to CorMedix Therapeutics

Advising firms

Deal team

20 lawyers named
LawyerFirmSeniorityPracticeOffice
Andrew Gilbert Lead DLA Piper Partner Not stated Not stated
Jeffrey Scharfstein Lead DLA Piper Partner Not stated Not stated
Emilio Ragosa Lead DLA Piper Partner Not stated Not stated
Carina Meleca Lead DLA Piper Partner Not stated Not stated
Gina Lee Lead DLA Piper Partner Not stated Not stated
Lisa Liu DLA Piper Associate Not stated Not stated
Thais Lopez DLA Piper Associate Not stated Not stated
Brian Sunberg DLA Piper Associate Not stated Not stated
Destiny Harrison DLA Piper Associate Not stated Not stated
Lauren Murdza DLA Piper Partner Not stated Not stated
Michelle Lara DLA Piper Partner Not stated Not stated
W. Kurtis Weaver DLA Piper Partner Not stated Not stated
Jeffrey Aronson DLA Piper Partner Not stated Not stated
Georgia Jolink DLA Piper Partner Not stated Not stated
Paolo Morante DLA Piper Partner Not stated Not stated
Richard Marks DLA Piper Partner Not stated Not stated
Jennifer Kashatus DLA Piper Partner Not stated Not stated
Preeya Pinto DLA Piper Partner Not stated Not stated
Christopher Mikson DLA Piper Partner Not stated Not stated
Bryna Shmerling DLA Piper Of counsel Not stated Not stated

17 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.

REGISTER FREE SIGN IN

Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.

Stated terms

Stated value
USD 145m (US$145 million)
What the figure measures
Total transaction value
Client
Heron TherapeuticsSell-side
Counterparties
CorMedix Therapeutics (Buy-side)